TransMedics Group (TMDX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$2.55 (+3.85%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of TransMedics Group (TMDX)
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Key Insights

Critical company metrics and information
  • Share Price

    $68.26
  • Market Cap

    $2.29 Billion
  • Total Outstanding Shares

    33.56 Million Shares
  • Total Employees

    584
  • Dividend

    No dividend
  • IPO Date

    May 2, 2019
  • SIC Description

    Electromedical & Electrotherapeutic Apparatus
  • Homepage

    https://www.transmedics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$37.44 Million
Net Cash Flow From Financing Activities$22.61 Million
Net Cash Flow From Investing Activities, Continuing$-157.51 Million
Exchange Gains/Losses$443000.00
Net Cash Flow From Operating Activities$37.44 Million
Net Cash Flow$-97.02 Million
Net Cash Flow From Financing Activities, Continuing$22.61 Million
Net Cash Flow From Investing Activities$-157.51 Million
Net Cash Flow, Continuing$-97.46 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Benefits Costs and Expenses$368.44 Million
Revenues$401.09 Million
Income/Loss From Continuing Operations Before Tax$32.65 Million
Research and Development$50.27 Million
Diluted Average Shares$35.26 Million
Net Income/Loss Attributable To Parent$32.64 Million
Operating Income/Loss$31.45 Million
Operating Expenses$206.54 Million
Diluted Earnings Per Share$0.93
Basic Average Shares$33.15 Million
Income/Loss From Continuing Operations After Tax$31.16 Million
Net Income/Loss$32.64 Million
Costs And Expenses$368.44 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Selling, General, and Administrative Expenses$156.27 Million
Income Tax Expense/Benefit$1.50 Million
Gross Profit$237.99 Million
Nonoperating Income/Loss$1.20 Million
Basic Earnings Per Share$0.98
Preferred Stock Dividends And Other Adjustments$0.00
Cost Of Revenue$163.10 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss Available To Common Stockholders, Basic$32.64 Million
Income Tax Expense/Benefit, Current$16000.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities And Equity$785.57 Million
Intangible Assets$2.20 Million
Other Current Liabilities$26.15 Million
Equity Attributable To Parent$209.92 Million
Other Non-current Assets$19.16 Million
Wages$20.77 Million
Other Current Assets$440.32 Million
Fixed Assets$271.74 Million
Current Assets$492.48 Million
Equity$209.92 Million
Liabilities$575.65 Million
Accounts Payable$13.13 Million
Noncurrent Liabilities$515.60 Million
Current Liabilities$60.05 Million
Inventory$52.15 Million
Equity Attributable To Noncontrolling Interest$0.00
Noncurrent Assets$293.10 Million
Assets$785.57 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.